ALACHUA, Fla., May 09, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced today that it has priced an underwritten public offering of 3,000,000 shares of its common stock, which was upsized from the previously announced 2,000,000 shares, at a price of $41.00 per share, resulting in gross proceeds (before underwriting discounts and offering expenses) to the Company of approximately $123,000,000. In addition, AxoGen has granted the underwriters a 30-day option to purchase up to an aggregate of 450,000 shares of common stock at the same price. The offering is expected to close on or about May 11, 2018, subject to satisfaction of customary closing conditions.

AxoGen intends to use the net proceeds from the proposed offering for long term facility and capacity expansion and general corporate purposes.

Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. William Blair & Company, L.L.C and JMP Securities LLC are acting as co-managers.